Jones Trading Maintains Buy on Pershing Square, Raises Price Target to $42
Jones Trading analyst Jason Weaver maintains Pershing Square (NYSE:PS) with a Buy and raises the price target from $39 to $42.
Read original at benzingaStocks · News reference
Bill Ackman Donates $400 Million in Pershing Square Stock to Build a Research Institute After His Daughter’s Severe Brain Hemorrhage
Bill Ackman gifted $400 million of his Pershing Square stake to a brain research foundation after his daughter's near-fatal hemorrhage.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 20, 2026, 10:33 AM
- Checked
- Aug 20, 2026, 11:25 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Warren Buffett Disciple Seth Klarman Bets on Cruise Lines, Auto Parts, Amazon and Bill Ackman in Q2
Value investor Seth Klarman reveals his latest stock picks in a second quarter filing for hedge fund Baupost Group.
Read original at benzingaBill Ackman Bets Big on Magnificent 7 Stocks, But Only Loves 3 of Them
Since 2023, Bill Ackman has been betting on the Magnificent Seven stocks with increased size and conviction. A look at his current favorites.
Read original at benzingaIBBQ vs. PBE: Which Biotech ETF Is the Better Buy?
The article compares two biotech ETFs from Invesco: IBBQ, which offers broad diversification across 251 companies with a low 0.19% expense ratio, and PBE, which takes a concentrated approach with 31 holdings and a higher 1.73% dividend yield. IBBQ is recommended for long-term investors seeking low-cost exposure, while PBE appeals to income-focused investors willing to pay higher fees for selective, momentum-driven picks.
Read original at the-motley-foolRegeneron Secures FDA Approval For Ultra-Rare Bone Disorder Drug
Regeneron Pharmaceuticals secured FDA approval for Pasatru, a novel monthly infusion therapy proven to reduce lesions in FOP patients.
Read original at benzingaRegeneron Pharmaceuticals Granted FDA Approval For Pasatru To Lower Formation Of New Heterotopic Ossification Lesions And Clinician-Assessed Flare-Ups In Adults With Fibrodysplasia Ossificans Progressiva
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the U.S. Food and Drug Administration (FDA) has granted approval for Pasatru™ (garetosmab-grts) to reduce formation of new heterotopic ossification (HO)
Read original at benzinga